Clinical Trials and Research

Injectable therapy shows consistent benefits across high-risk ATTR-CM groupsNew analyses back the use of the approved therapy Amvuttra (vutrisiran) as an initial…

–    Of first 20 patients, all four MRD-negative patients have converted to complete response (CR)  ––   CR rate now 95% (19 of 20…

Multiparametric scores are effective for validating the AL score and increased wall thickness (IWT) scores in AL amyloidosis, according to a study being presented…

The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics,…

This CardiaCast episode explores the latest advances in transthyretin amyloid cardiomyopathy (ATTR-CM) presented at ACC.26, with a focused review of newly released…

Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative cardiomyopathy that may occur in hereditary or wild-type forms. Although more than 150…

AbstractObjective To assess the clinical value of dual-time-point planar imaging and SPECT/CT tomographic imaging of 99mTc-PYP in diagnosing transthyretin cardiac…

AbstractThe pathogenic transthyretin (TTR) gene variant c.182G>T, p.Trp61Leu (Trp61Leu) was previously reported once, as variant transthyretin amyloidosis (ATTRv…

OverviewAll ATTRwt patients on tafamidis 61 mg treatment will be clinically evaluated before treatment initiation and subsequently every six months for the…

AbstractSystemic amyloid light-chain (AL) amyloidosis is characterized by the extracellular deposition of misfolded immunoglobulin light chains in tissues and is…